Cross-reactive T-helper responses in patients infected with different subtypes of human immunodeficiency virus type 1

Journal of Virology

Volumn 74, Issue 10, 2000, Pages 4888-4890

  Leandersson, Ann Charlotte ^a   Gilljam, Gustav ^a   Fredriksson, Malin ^a   Hinkula, Jorma ^a   Alaeus, Annette ^b   Lidman, Knut ^b   Albert, Jan ^a   Bratt, Göran ^c   Sandström, Eric ^c   Wahren, Britta ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELLULAR IMMUNITY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL;

AIDS VACCINES; CROSS REACTIONS; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, HELPER-INDUCER; VACCINATION; VACCINES, SYNTHETIC;

EID: 0034002852     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.10.4888-4890.2000     Document Type: Article

References (23)

1. Alaeus, A., T. Leitner, K. Lidman, and J. Albert. 1997. Most HIV-1 genetic subtypes have entered Sweden. AIDS 11:199-202.
2. Autran, B., G. Carcelain, T. S. Li, C. Blanc, D. Mathez, R. Tubiana, C. Katlama, P. Debre, and J. Leibowitch. 1997. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112-116.
3. Carlesimo, M., O. Pontesilli, A. R. Varani, M. L. Bernardi, A. M. Mazzone, R. Rosso, E. C. Guerra, A. Cassone, R. Paganelli, and F. Aiuti. 1997. CD28 costimulation and T lymphocyte proliferative responses in HIV-1 infection. Clin. Exp. Immunol. 109:406-411.
4. Fernandez, M. H., S. J. Fidler, R. J. Pitman, J. N. Weber, and A. D. Rees. 1997. CD4+ T-cell recognition of diverse clade B HIV-1 isolates. AIDS 11:281-288.
5. Furtado, M. R., D. S. Callaway, J. P. Phair, K. J. Kunstman, J. L. Stanton, C. A. Macken, A. S. Perelson, and S. M. Wolinsky. 1999. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 340:1614-1622.
6. Gilljam, G., A. Svensson, A. Ekstrom, and B. Wahren. 1999. Immunological responses to envelope glycoprotein 120 from subtypes of human immunodeficiency virus type 1. AIDS Res. Hum. Retrovir. 15:899-907.
7. Gotch, F. 1998. Cross-clade T cell recognition of HIV-1. Curr. Opin. Immunol. 10:388-392.
8. Korber, B., B. Foley, T. Leitner, J. W. Mellors, F. McCutchan, B. Hahn, G. Myers, and C. Kuiken. 1998. Human retroviruses and AIDS 1997: a compilation and analysis of nucleic acid and amino acid sequences. Los Alamos National Laboratory, Los Alamos, N.M.
9. Leandersson, A. C., G. Bratt, J. Hinkula, G. Gilljam, P. Cochaux, M. Samson, E. Sandstrom, and B. Wahren. 1998. Induction of specific T-cell responses in HIV infection. AIDS 12:157-166.
10. Leitner, T., G. Korovina, S. Marquina, T. Smolskaya, and J. Albert. 1996. Molecular epidemiology and MT-2 cell tropism of Russian HIV type 1 variant. AIDS Res. Hum. Retrovir. 12:1595-1603.
11. Markowitz, M., M. Vesanen, K. Tenner-Racz, Y. Cao, J. M. Binley, A. Talal, A. Hurley, X. Jin, M. R. Chaudhry, M. Yaman, S. Frankel, M. Heath-Chiozzi, J. M. Leonard, J. P. Moore, P. Racz, D. F. Nixon, and D. D. Ho. 1999. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J. Infect. Dis. 179:527-537.
12. Mittler, J. E., M. Markowitz, D. D. Ho, and A. S. Perelson. 1999. Improved estimates for HIV-1 clearance rate and intracellular delay. AIDS 13:1415-1417.
13. Moss, R. B., W. Giermakowska, P. Lanza, J. L. Turner, M. R. Wallace, F. C. Jensen, G. Theofan, S. P. Richieri, and D. J. Carlo. 1997. Cross-clade immune responses after immunization with a whole-killed gp120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects. Viral Immunol. 10:221-228.
14. Musey, L. K., J. N. Krieger, J. P. Hughes, T. W. Schacker, L. Corey, and M. J. McElrath. 1999. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J. Infect. Dis. 180:278-284.
15. Plana, M., F. Garcia, T. Gallart, J. M. Miro, and J. M. Gatell. 1998 Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study. Lancet 352:1194-1195.
16. Ratto-Kim, S., K. V. Sitz, R. P. Garner, J. H. Kim, C. Davis, N. Aronson, N. Ruiz, K. Tencer, R. R. Redfield, and D. L. Birx. 1999. Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response. J. Infect. Dis. 179:337-344.
17. Redfield, R. R., D. L. Birx, N. Ketter, E. Tramont, V. Polonis, C. Davis, J. F. Brundage, G. Smith, S. Johnson, A. Fowler, et al. 1991. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N. Engl. J. Med. 324: 1677-1684.
18. Rinaldo, C., X.-L. Huang, Z. Fan, M. Ding, L. Beltz, A. Logar, D. Panicali, G. Mazzara, J. Liebmann, and M. Cottrill. 1995. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69:5838-5842.
19. Rosenberg, E. S., J. M. Billingsley, A. M. Caliendo, S. L. Boswell, P. E. Sax, S. A. Kalams, and B. D. Walker. 1997. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278:1447-1450.
20. Sandstrom, E., and B. Wahren. 1999. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebocontrolled trial. Nordic VAC-04 Study Group. Lancet 353:1735-1742.
21. Shearer, G. M., and M. Clerici. 1991. Early T-helper cell defects in HIV infection. AIDS 5:245-253.
22. Valentine, F. T., S. Kundu, P. A. Haslett, D. Katzenstein, L. Beckett, C. Spino, B. Borucki, M. Vasquez, G. Smith, J. Korvick, J. Kagan, and T. C. Merigan. 1996. A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). J. Infect. Dis. 173:1336-1346.
23. Wahren, B., L. Morfeldt-Mansson, G. Biberfeld, L. Moberg, P. Ljungman, S. Nordlund, U. Bredberg-Raden, A. Werner, J. Lower, and R. Kurth. 1986. Impaired specific cellular response to HTLV-III before other immune defects in patients with HTLV-III infection. N. Engl. J. Med. 315:393-394.